Janux Therapeutics (JANX) Cash from Investing Activities (2021 - 2026)

Janux Therapeutics (JANX) has 6 years of Cash from Investing Activities data on file, last reported at $8.3 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 102.43% year-over-year to $8.3 million in Q1 2026; TTM through Mar 2026 was $47.7 million, a 109.84% increase from a year earlier, with the FY2025 full-year figure at -$301.0 million, down 16.65% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $8.3 million, down from $29.5 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for JANX reached as high as $33.9 million in Q4 2024 and fell as low as -$340.4 million in Q1 2025.
• Historically, Cash from Investing Activities has averaged -$31.4 million across 5 years, with a median of $8.3 million in 2025.
• Across the five-year window, Cash from Investing Activities jumped 20405.88% in 2022 and slumped 1201.33% in 2024, its largest moves.
• Year by year, Cash from Investing Activities stood at -$1.6 million in 2022, then soared by 793.45% to $11.1 million in 2023, then jumped by 205.01% to $33.9 million in 2024, then dropped by 12.92% to $29.5 million in 2025, then plunged by 71.95% to $8.3 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were $8.3 million in Q1 2026, $29.5 million in Q4 2025, and $8.3 million in Q3 2025.